Acamprosate calcium is an active ingredient used to support individuals who are trying to maintain abstinence from alcohol. In Hong Kong, it is available by prescription as a 333 mg pill. The medication belongs to the addiction-treatment class and is commonly prescribed to people who have completed detoxification and aim to reduce the risk of relapse.
Acamprosate’s primary action is to help restore the balance of neurotransmitters that is disrupted by chronic alcohol use. Specifically:
Acamprosate is not a sedative; its effects are felt gradually, typically within a few weeks of regular use. The drug is absorbed well from the gastrointestinal tract, does not undergo significant metabolism, and is eliminated unchanged by the kidneys.
Acamprosate calcium is approved for the following indication in Hong Kong:
It is used as part of a comprehensive treatment plan that includes counseling, support groups, and other psychosocial interventions. The medication is intended for adults who have achieved initial sobriety and wish to sustain it over the long term.
Acamprosate is excreted unchanged by the kidneys, so it has relatively few pharmacokinetic interactions. Nevertheless:
If you are taking other prescription or over-the-counter medicines, inform your healthcare provider before starting acamprosate.
If a dose is missed, take it as soon as you remember unless it is close to the time for your next scheduled dose. Do not double the dose to make up for a missed tablet.
Symptoms of overdose may include severe nausea, vomiting, diarrhea, or dizziness. If an overdose is suspected, seek emergency medical care. Treatment is supportive; there is no specific antidote.
Acamprosate can be stopped without tapering, but discontinuation should be discussed with a healthcare provider, especially if you are still in early recovery. Stopping abruptly may increase the risk of cravings.
This article provides educational information about acamprosate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Mild to moderate renal impairment may require a reduced dose (one 333 mg tablet three times daily). Your doctor will assess kidney function and adjust the regimen accordingly.
Acamprosate is not known to cause sedation. However, if you experience dizziness or severe nausea, you should avoid operating machinery until the symptoms resolve.
Clinical guidelines suggest continuing the medication for at least six months to a year, depending on individual progress and risk of relapse. Your healthcare provider will tailor the duration to your needs.
Safety data are limited. It should only be used if the potential benefit outweighs any risk to the fetus or infant, and only under close medical supervision.
There are no known pharmacokinetic conflicts, but combining treatments should be coordinated by a clinician to monitor efficacy and side effects.
Do not double the next scheduled dose. If you feel unwell or notice severe symptoms, seek medical attention promptly.
Acamprosate has minimal interaction, but NSAIDs can affect kidney function, which is relevant because acamprosate is renally cleared. Discuss any regular NSAID use with your provider.
The drug’s half-life is relatively short, so multiple daily doses maintain steady blood levels that help control cravings throughout the day.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of any country-specific regulations on controlled substances.
Acamprosate primarily modulates glutamate and GABA balance to reduce cravings, while disulfiram blocks alcohol metabolism and naltrexone blocks opioid receptors linked to reward pathways. The choice of therapy depends on individual response and medical history.
